Qtrex Quantum Ltd. · NASDAQ:QTEX
Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (September 2021)
21 slides from Qtrex Quantum's investor presentation, Sep 13, 2021
Slide 1: Inspira Technologies OXY B.H.N Ltd. (IINN, IINNW)
Inspira Technologies OXY B.H.N Ltd. (IINN,IINNW) P 1 roprietary - Inspira Technologies Oxy B.H.N. Ltd.
Slide 2: Forward-looking statements disclaimer
This presentation of Inspira Technologies Oxy B . H . N . Ltd . (the “Company” or “Inspira”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law . Words such as “expects,” “intends,” “plans,” “believes,” “seeks,” “estima
Slide 3: A medical device company in the potential $30Bn respiratory care market
3 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. A medical device company operating in the potential $30Bn* respiratory care market Inspira is developing the ART device, an early extracorporeal respiratory support system with an intent to function as an “Artificial Lung” and prevent the need for
Slide 4: I have experienced COVID
I have exp e ri e n c ed COVID …together with 222,840,110 other people around the world …and so did a childhood friend who suffered complications and ended up on Mechanical Ventilation The fam i ly sa ys it is a m iracle he s u rviv ed it 4 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. https://
Slide 5: Bringing hope to millions
“Bringing hope to millions” * Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017 Mechanical Ventilation (MV) 5 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. An estimated 20 million people worldwi
Slide 6: Early Extracorporeal Respiratory Support
Ea r l y Ext r ac o r p o re al R e s p ir ato r y S u pp o r t Designed to elevate & stabilize declining oxygen saturation levels in one minute , while the patient remains awake, & breathing * 6 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. *Based on CRO study results. The ART500 has yet to be
Slide 7: Designed to Prevent the Need for MV
Designed to Prevent the Need for MV Play V ideo 7 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. The product is currently in a developmental stage and has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or CE.
Slide 8: Assisted Breathing Respiratory Support Treatments
A ss is t ed B r ea t hing Respiratory Support Treatments 8 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. Non In v asive ¹ In v asive M echani cal Ven t ila t ion ² HF Nasal cannula O x y g e n M as k CPAP/BIPAP Extracorporeal Membrane Oxygenation (ECMO) ³ V - V o r V - A 1 ST LINE 2 ND LINE LA
Slide 9: Competitive Advantage
Competitive Advantage 9 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. Unique New Solution Designed to minimize need for Mechanical Ventilation and reduce hospital days Reducing Risks Expected to avoid the lengthy weaning process from Mechanical Ventilation Awake patient Expected to avoid risk o
Slide 10: Expanding $30Bn respiratory care market beyond ICUs
Expanding $30Bn¹ respiratory care market beyond ICUs Making acute respiratory treatment available in locations and medical facilities without ICUs Emergency Medical Services Small Urban & Rural Hospitals General Medical Units Intensive Care Units 1. “Respiratory Care Devices Market by Product”. Repo
Slide 11: First Introduction and additional applications
First Intr oduct ion* C o m p o n e n ts & ad i t i o n al ap pli c at i o n s ART New Intent of Use - Total adresable market of $20Bn ART Sup p o r t ECLS 2022 2024 2023 *Estimates and may be subject to change . The product is currently in a developmental stage and has not yet been tested or used i
Slide 12: Razor Blade Business Model
“ R a zo r Bl a d e ” Busi n e s s Model X 15 N o vel T ech n o lo g y ART Dis p o s a b le resp i rat o ry support units + 20 mi l l i o n g lo b al l y per year² 1,25 0 $* p er treatment $20Bn T o t a l Add r es s able Market 12 Proprietary - Inspira Technologies Oxy B.H.N. Ltd. 2. Forum of Intern
Slide 13: Reimbursement Strategy
Reimb u rs e ment St rategy Inspira plans to utilize existing CPT Codes using a “New Approach” to an existing procedure Red u ced p atient complications Reduced length of stay & re - admissions Reduced costs & o p erati o n a l ex p enses Red u ced h o sp i tal & staff burden cms.gov: MS DRG based r
Slide 14: Inspira's Proprietary Sub-Dynamic Technology
Inspira’s Proprietary Sub - Dynamic Technology Includes proprietary innovative features to prevent hemolysis & thrombosis Direct Blood Oxygenation ~200cc of blood are being enriched at any given point, providing the patient a saturation boost within 1 minute Blood Circulation Actuated blood flow to
Slide 15: Dual Lumen Cannula & Adjustable Dual Lumen; ART components
Dual Lumen Cannula & Adjustable Dual Lumen Component: Low impact radiography free dual lumen cannula with anti air - embolism mechanism * A Sub - Dynamic Pump Component: Proprietary low flow pump preventing hemolysis & thrombosis Initiation System Component: Autonomous initiation system for self pri
Slide 16: Regulatory Clearance (Multi-Step approach)
Q 4 - 2021 Q 4 - 2022 Q 3 - 2023 Components 510(k) ART 510(k) S uppo r t E CL S ART De N ov o* N e w Inte nt o f U s e ? CE Regulatory Clearance (Multi - Step approach) To - date the ART has not been tested on humans and is subject to the regulator’s requirement. *Will require a new 510(k) marketing
Slide 17: Go-To-Market Strategy for Market Entry
* Trademarks are the property of their respective owners. Go - To - Market Strategy for Market Entry Establishing multiple recurring revenue streams across medical sectors & markets Collaborating with top ranked hospitals to expose ART, attain both clinical endorsement & adoption Identified customer
Slide 18: Targeting Major Milestones
» » » » » Q 4 - 2021 » FDA Fil ing C o m ponent 510 (k) » Distribution Agreement » I n te lle c tu a l Property H1 - 2022 » Strategic Agreement » Distribution Agreement » Component Dep l oyme n t H 2 - 2022 » FDA 510 ( k ) Fi l in g s - ART s u pp o r t EC L S - Components » Distrib u ti on Agreemen
Slide 19: Leadership Team
Lead e rs h ip Team P r of . B e nad Go l dwa s s er , M D, M B A Chairman U r o l o gic s urge o n, inv e nt o r , e ntrep r en e ur & v e ntu r e capit a l inv e s t o r . L e a ding high gr owth , publicly traded medical companies. C o - fo unde d V id a m e d Inc . , a cqui red by M e dt r o nic
Slide 20: Highlights
Highlights • Innovative and cost - effective respiratory technology • Early saturation elevation to prevent the use of MV • Patients treated while awake & breathing spontaneously • Raises saturation levels in 1 minute • Reduces hospitalization stay and treatment costs • Total addressable market of $
Slide 21: Thank You
Thank You Joe Hayon Co - Founder, President & CFO E - mail: joe@inspirao2.com www.inspira - technologies.com
Inspira Technologies OXY B.H.N. — Investor Presentation (September 2021) on 6ix